253 related articles for article (PubMed ID: 20010156)
1. C-reactive protein and cardiovascular diseases--is it ready for primetime?
Lavie CJ; Milani RV; Verma A; O'Keefe JH
Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
[TBL] [Abstract][Full Text] [Related]
2. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
3. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.
Savarese G; Rosano GM; Parente A; D'Amore C; Reiner MF; Camici GG; Trimarco B; Perrone-Filardi P
Int J Cardiol; 2014 Nov; 177(1):152-60. PubMed ID: 25499365
[TBL] [Abstract][Full Text] [Related]
4. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
5. Role of C-reactive protein when prescribing a statin.
Kinlay S
Curr Atheroscler Rep; 2012 Feb; 14(1):26-32. PubMed ID: 22125118
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
7. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein.
Dandona P
Mayo Clin Proc; 2008 Mar; 83(3):333-42. PubMed ID: 18316001
[TBL] [Abstract][Full Text] [Related]
9. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein.
Jeong HC; Ahn Y; Hong YJ; Kim JH; Jeong MH; Kim YJ; Chae SC; Cho MC;
Int J Cardiol; 2013 Sep; 167(5):1848-53. PubMed ID: 22592028
[TBL] [Abstract][Full Text] [Related]
10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein (CRP)-lowering agents.
Prasad K
Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
[TBL] [Abstract][Full Text] [Related]
14. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A; Limmert T; Hoffmann U
Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
[TBL] [Abstract][Full Text] [Related]
15. I've heard that statins can can help lower C-reactive proteins (CRP) levels. I'm 65, but I don't take a statin because my cholesterol is low. Should I be concerned about CRP? I have a family history of heart disease.
Heart Advis; 2011 Feb; 14(2):8. PubMed ID: 22957365
[No Abstract] [Full Text] [Related]
16. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
17. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
Koenig W
Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Patrick L; Uzick M
Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
[TBL] [Abstract][Full Text] [Related]
19. [C-reactive protein in coronary plaques -- prevalence with acute coronary syndrome].
Andrié R; Maylahn M; Braun P; Lüderitz B; Bauriedel G
Z Kardiol; 2002 Nov; 91(11):913-20. PubMed ID: 12442194
[TBL] [Abstract][Full Text] [Related]
20. [From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
Márk L; Katona A
Orv Hetil; 2009 Nov; 150(44):2012-8. PubMed ID: 19861287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
